FierceBiotech

Invitae launches personalized cancer blood tests to spot tumor relapses

Invitae has launched a cancer blood test designed to detect the minimal residual disease left over from solid tumors to help gauge a patient’s risk of recurrence and track their response to treatments ...
MedCity News

Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
Fox 5 San Diego

Invitae Launches its First CE-IVD Cancer Testing Kits In Europe

SAN FRANCISCO, Feb. 16, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx ® and LiquidPlex Dx ™ in Europe, part of its ...
FierceBiotech

Invitae claims FDA nod for blood test that checks for genetic risks of multiple hereditary cancers

Invitae has collected a de novo clearance from the FDA for a blood test designed to detect hundreds of potential genetic markers to help evaluate whether a person carries an increased risk of ...
Business Wire

Invitae Announces Major Expansion of Its Test Menu for Neurological, Pediatric, and Rare Genetic Conditions and Introduces New Panels for Inherited Metabolic Disorders and ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...